Study guide

5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization

Key Takeaways Explain This Topic AI

The CDC U.S. Medical Eligibility Criteria for Contraceptive Use (US MEC) stratifies safety across four distinct categories: Category 1 (unrestricted use) to Category 4 (unacceptable health risk / absolute contraindication).

Combined hormonal contraceptives (CHCs) are strictly Category 4 in postpartum individuals <21 days, smokers aged ≥35 consuming ≥15 cigarettes/day, patients with severe hypertension (≥160/100 mmHg or vascular disease), personal history of VTE/PE, thrombogenic mutations, ischemic heart disease/stroke, migraine with aura at any age, active breast cancer, and severe decompensated cirrhosis.

Patients presenting with Category 4 contraindications to CHCs can safely utilize non-hormonal Copper IUDs (Category 1) or progestin-only modalities (LNG-IUS, etonogestrel implant, POPs; typically Category 1 or 2).

Laparoscopic bilateral salpingectomy is the contemporary standard of care for female permanent contraception, conferring complete irreversible sterility while significantly lowering lifetime epithelial ovarian cancer risk via excision of the fimbriated fallopian tubes.

Federal Medicaid sterilization regulations (Title 42 CFR) mandate a strict 30-day waiting period post-consent, minimum age 21, and mental competence, while male vasectomy requires post-procedure semen analysis at 8–12 weeks to document complete azoospermia.

Last updated: October 2026

CDC U.S. Medical Eligibility Criteria (US MEC) Categorization Framework

The Centers for Disease Control and Prevention (CDC) U.S. Medical Eligibility Criteria for Contraceptive Use (US MEC) provides evidence-based safety guidance for contraceptive prescribing in individuals with medical conditions across four numeric tiers:

Category 1: A condition for which there is no restriction for the use of the contraceptive method.

Category 2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks.

Category 3: A condition where the theoretical or proven risks usually outweigh the advantages . The method is not recommended unless other more appropriate methods are unavailable or unacceptable. Requires specialized clinical judgment and close surveillance.

Category 4: A condition that represents an unacceptable health risk if the contraceptive method is used. This constitutes an absolute medical contraindication .

Major US MEC Category 4 Contraindications for CHCs

Combined hormonal contraceptives (COCs, transdermal patch, vaginal rings) carry thromboembolic and cardiovascular risks driven by hepatic estrogen-mediated coagulation factor synthesis. Clinicians must recognize critical Category 4 conditions:

Medical Condition / Risk Factor US MEC Rating for CHCs Pathophysiologic Rationale Safe Tier 1 & Tier 2 Alternatives

Postpartum < 21 Days (Breastfeeding or non-breastfeeding) Category 4 Profound postpartum hypercoagulability; estrogen sharply amplifies early venous thromboembolism (VTE) risk. Progestin-only pills, etonogestrel implant, LNG-IUS, Copper IUD (all Cat 1 or 2).

Age ≥ 35 & Smoking ≥ 15 Cigarettes/Day Category 4 ( Category 3 if <15 cigs/day ) Synergistic, exponential increase in myocardial infarction, stroke, and arterial thrombosis. Copper IUD (Cat 1), LNG-IUS (Cat 1), Implant (Cat 1), POPs (Cat 1).

Severe Hypertension (Systolic ≥160 or Diastolic ≥100 mmHg, or with vascular disease) Category 4 ( Category 3 if SBP 140–159 / DBP 90–99 or well-controlled ) Estrogen stimulates hepatic angiotensinogen production, worsening arterial pressure and stroke risk. Copper IUD (Cat 1), LNG-IUS (Cat 1/2), Implant (Cat 1/2), POPs (Cat 1/2).

Acute VTE, or past DVT/PE with higher recurrence risk (not on anticoagulation) Category 4 ( Category 3 if lower recurrence risk ) Markedly heightened baseline risk of recurrent life-threatening thromboembolism. Copper IUD (Cat 1), LNG-IUS (Cat 2), Implant (Cat 2), POPs (Cat 2).

Known Thrombogenic Mutations (Factor V Leiden, Prothrombin G20210A, Protein S/C/Antithrombin deficiency) Category 4 Compounded congenital thrombophilia confers unacceptable VTE risk. Copper IUD (Cat 1), LNG-IUS (Cat 2), Implant (Cat 2), POPs (Cat 2).

Ischemic Heart Disease, History of Stroke, or Complicated Valvular Heart Disease Category 4 Estrogen accelerates arterial thrombosis, endothelial dysfunction, and platelet aggregation. Copper IUD (Cat 1), LNG-IUS (Cat 2/3), Implant (Cat 2/3), POPs (Cat 2).

Migraine with Aura (At Any Age) Category 4 ( Migraine without aura: Cat 2 if <35; Cat 3 if ≥35 ) Cortical spreading depression and vasospasm compounded by estrogen confers a 2- to 8-fold increase in ischemic stroke risk. Copper IUD (Cat 1), LNG-IUS (Cat 2), Implant (Cat 2), POPs (Cat 2).

Current Breast Cancer Category 4 for ALL Hormonal Methods ( Past breast cancer disease-free 5 yr: Cat 3 ) Breast carcinomas frequently express steroid receptors; exogenous hormones stimulate tumor proliferation. Copper IUD (Category 1) is the sole Tier 1 method permitted.

Severe Decompensated Cirrhosis, Hepatic Adenoma, or Liver Tumors Category 4 Impaired steroid clearance; estrogen promotes hepatic adenoma growth and rupture. Copper IUD (Cat 1).

Diabetes with Nephropathy, Retinopathy, Neuropathy, Vascular Disease, or >20 yr Duration Category 3 or 4 Accelerated microvascular and macrovascular atherogenesis and thrombosis. Copper IUD (Cat 1), LNG-IUS (Cat 2), Implant (Cat 2), POPs (Cat 2).

Important

When combined hormonal methods are contraindicated, progestin-only options (subdermal implant, LNG-IUS, POPs) and the non-hormonal copper IUD provide safe, highly effective alternatives because they do not induce hepatic procoagulant protein synthesis.

  • Permanent Contraception: Female Sterilization
  • Laparoscopic Bilateral Salpingectomy

Complete surgical excision of both fallopian tubes is now the preferred standard of care over tubal occlusion (ligation or clips) during interval laparoscopic permanent contraception. Beyond providing irreversible contraception with near-zero failure rates, bilateral salpingectomy significantly reduces lifetime risk of epithelial ovarian cancer (by 50% to 65%) , because high-grade serous carcinomas originate primarily in the distal fimbriated fallopian tubal epithelium. ACOG's August 2026 Clinical Practice Update names complete bilateral salpingectomy the preferred permanent contraception procedure and recommends routine salpingectomy at hysterectomy for patients at average ovarian cancer risk.

Bilateral Tubal Ligation (BTL)

Techniques: Segmental excision via the Pomeroy technique (ligating a mid-ampullary tubal loop with absorbable suture and resecting the loop) or Parkland technique (separate mesenteric window ligations and segmental resection); mechanical occlusion via Filshie clips or Falope rings .

Failure Rates & Ectopic Risk: The CREST study demonstrated a 10-year cumulative failure rate of ~1.8% (highest in women sterilized at younger ages). If pregnancy occurs following tubal ligation, approximately one-third of pregnancies are ectopic .

Postpartum Sterilization: Performed via an infraumbilical minilaparotomy within 24 to 48 hours of vaginal delivery, taking advantage of fundal proximity to the umbilicus.

Title 42 CFR Federal Medicaid Sterilization Regulations

To prevent reproductive coercion, federal regulations (Title 42 CFR Part 50) govern all sterilizations funded by Medicaid:

Age Requirement: The patient must be at least 21 years of age when the consent is signed.

Mental Competence: The patient must be mentally competent; consent cannot be signed by a legal guardian.

Mandatory 30-Day Waiting Period: A minimum of 30 full days must elapse between consent signing and surgery.

Exceptions: Premature delivery or emergency abdominal surgery permits a shortened interval of at least 72 hours , provided consent was signed at least 30 days before the expected delivery date.

Validity Interval: Signed consent remains valid for 180 days .

Prohibited Situations: Consent CANNOT be obtained during active labor, childbirth, or while seeking/undergoing abortion.

Permanent Contraception: Male Sterilization (Vasectomy)

Vasectomy involves surgical interruption, transection, ligation, or cautery of the bilateral vas deferens within the scrotum under local anesthesia.

Clinical Advantages: Simpler, safer, faster, and more cost-effective than female sterilization, with lower complication rates (<1%) and no need for general anesthesia or peritoneal entry.

Post-Vasectomy Azoospermia Protocol: Vasectomy is not immediately effective . Residual sperm stored in the ampulla of the vas deferens remain viable for weeks. The couple must use alternate contraception until a post-vasectomy semen analysis (PVSA) at 8 to 12 weeks post-procedure (or after ~20 ejaculations) confirms complete azoospermia (or rare non-motile sperm <100,000/mL).